Pfizer receives backing for late-stage trial of kidney cancer drug in Asia - CanadianBusiness.com PDF Print
CanadianBusiness.com
The study will focus on patients at high risk of recurrent renal cell carcinoma following a nephrectomy, or removal of the kidneys. Pfizer, based in New York, is seeking Food and Drug Administration approval to market the drug for advanced renal cell ...
SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.